the aid library

LIST OPTIONS

Filter

4890

Vitamin Deficiency and Tuberculosis: Need for Urgent Clinical Trial for Managment of Tuberculosis

S. Chakraborty, K. Syal, R. Bhattacharyya, et al. (2014) CC

Review Article: Journal of Nutritional Health & Food Science Vitamin Deficiency and Tuberculosis: Need for Urgent Clinical Page 1- 6

Download (148)

View PDF (205)

Mudança do clima e terra

International Panel on Climate Change IPCC (2019) C2

Relatório especial do IPCC sobre mudança do clima, desertificação, degradação da terra, manejo sustentável da terra, segurança alimentar, e fluxos de gases de efeito estufa em ecossistemas terrestres

Download (380)

View PDF (598)

Trends in Child Health in Nigeria, 2003– 2013

Winter, Rebecca, Akinlo, Ambrose, and Lia Florey ICF International (2016) C2

DHS Further Analysis Reports No. 103

Download (150)

View PDF (205)

Recomendações provisórias para o uso da vacina ChAdOx1-S [recombinante] contra COVID-19 (vacina AstraZeneca COVID-19 AZD1222 Vaxzevria™, SII COVISHIELD™) - Última atualização em 30 de julho de 2021

OPAS, OMS OPAS (2021) CC

Interim recommendations for the use of ChAdOx1-S [recombinant] COVID-19 vaccine (AstraZeneca COVID-19 AZD1222 Vaxzevria™, SII COVISHIELD™ vaccine) - Last updated 30 July 2021

Download (614)

View PDF (703)

A case study of the Essential Health Benefit in Tanzania mainland

Todd G.; Nswilla A.; Kisanga O.; Mamdani M. Regional Network for Equity in Health in east and southern Africa (EQUINET) (2017) C1

Regional Network for Equity in Health in east and southern Africa (EQUINET): Disussion Paper 109
This report describes the evolution of mainland Tanzania’s EHB; the motivations for developing the EHBs, the methods used to develop, define and cost them; how it is being disseminated, communicat... more

Download (379)

View PDF (309)

Community-facility Linkages to Support the Scale up of Lifelong Treatment for Pregnant and Breastfeeding Women Living with HIV: A Conceptual Framework, Compendium of Promising Practices and Key Operat

Ackerman Gulaid, Laurie United Nations Children’s Fund (UNICEF) (2015)

Download (150)

View PDF (219)

Venezuela: Plan de Respuesta Humanitaria con Panorama de Necesidades 2020

Office for the Coordination of Humanitarian Affairs OCHA (2020) CC

El Plan de Respuesta Humanitaria con Panorama de Necesidades Humanitarias Venezuela 2020 tiene por objeto proporcionar asistencia humanitaria a 4,5 millones de venezolanos y venezolanas vulnerables. Para ello, hace un llamado de $762,5 millones de dólares. El Plan se basa en la labor humanitaria qu... more

External Link

Acute Chagas Disease: New Global Challenges for an Old Neglected Disease

Andrade, D.; Gollob, K.; Dutra, W. PLoS Neglected Tropical diseases (2015) CC

Abstract: Chagas disease is caused by infection with the protozoan Trypanosoma cruzi, and although over 100 years have passed since the discovery of Chagas disease, it still presents an increasing problem for global public health. A plethora of information concerning the chronic phase of human Chaga... more

Download (241)

View PDF (392)

European Drug Report 2019: trends and developments.

European Monitoring Centre for Drugs and Drug Addiction European Union (2019) C1

The Trends and Developments report presents a top-level overview of the drug phenomenon in Europe, covering drug supply, use and public health problems as well as drug policy and responses. Together with the online Statistical Bulletin and 30 Country Drug Reports, it makes up the 2019 European Drug ... more

Download (214)

View PDF (304)

Trastorno por déficit de atención con hiperactividad

T. S. Moriyama; A. J. M. Cho; R. E. Verin; et al. IACAPAP (2017) C2

Trastornos externalizantes Capítulo D.1 Edición: Matías Irarrázaval & Andrés Martín Traducción: Fernanda Prieto Tagle, Marta García Acuña

Download (1375)

View PDF (1561)

Basic Epidemiology

Bonita, R.; R.Beaglehole, and T. Kjellström World Health Organization WHO (2006) C_WHO

2nd edition

Download (345)

View PDF (456)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (476)

View PDF (649)

Toolkit on disability for AFRICA: INFORMATION AND COMMUNICATION TECHNOLOGY (ICT) AND DISABILITY

United Nations Division for Social Policy Development (DSPD) & United Nations Department of Economic and Social Affairs (DESA) (2016) C1

Module 12

Download (1587)

View PDF (2724)

The Pediatric Clinical Manual

Elaine Abrams, Wafaa El-Sadr, and Miriam Rabkin The International Center for AIDS Programm (2004)

Download (925)

View PDF (1689)

RECOMENDACIONES SOBRE TEMAS DE ÉTICA EN OBSTETRICIA Y GINECOLOGÍA Hechas por el Comité Para El Estudio de los Aspectos Éticos dela Reproducción Humana dela FIGO

FIGO (2012)

'Ethical Issues in Obstetrics and Gynecology' represents the results of carefully researched and considered discussion. The guidelines are intended to provide material for consideration and debate about ethical aspects of our discipline for member organisations and their constituent membership.